Polycythemia vera: Difference between revisions
Jump to navigation
Jump to search
imported>Aleksander Stos (cleanup) |
imported>Subpagination Bot m (Add {{subpages}} and remove any categories (details)) |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
== Clinical criteria == | == Clinical criteria == | ||
| Line 8: | Line 10: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 10:31, 13 November 2007
Clinical criteria
JAK2 mutations
Mutations in the JAK2 gene, specifically at the V617F locus, give rise to myeloproliferative disorders such as essential thrombocythemia and polycythemia vera.[1]
Authors reported[2] that other mutations of the coding region of the JAK2 gene could create a polycythemia phenotype.